On CNBC's "Cramer's Mad Dash" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, took at look at this "classic growth stock."
The stock has had trouble gaining upside momentum due to rising coffee costs, he reasoned.
However, CEO Howard Schultz has had to deal with rising input costs before, and has well positioned his company to deflect this rapid rise.Cramer added that investors are not paying too much for shares of Starbucks at current levels and he likes this analyst's call "very much." Turning to Celgene (CELG), Credit Suisse boosted its price target on the stock to $225 from $210. The analyst reasoned that Celgene's pipeline is not being fully recognized, and Cramer seemed to agree. The advancements in creating possible cures for Crohn's disease and psoriatic arthritis are incredible and could be huge for Celgene, he concluded. -- Written by Bret Kenwell in Petoskey, Mich. Follow @BretKenwell IBM Fights for Respect and Relevance on Rough Seas of Investor Confidence Why Big Car Companies Don't Give A Rat's Ass About Tesla 5 Reasons to Change Your Outlook on Emerging Markets Why SolarCity Is Shining Once Again for Investors
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts